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Human Fibrosarcoma HT-1080The potential applications of Fe3O4magnetite nanoparticles (MNPs) in nanomedicine as drug delivery systems
are well known. In this study we prepared umbelliprenin-coated Fe3O4 MNPs and evaluated the
antiproliferative effect of combination in vitro. After synthesis of Fe3O4 MNPs, particles were characterized
by transmission electron microscopy, energy-dispersive spectroscopy, and X-ray diffraction spectroscopy
techniques. The natural candidate compound — umbelliprenin— was isolated and identiﬁed and
umbelliprenin-coated Fe3O4 MNPs were prepared, using precipitation method. The surface chemistry of
umbelliprenin-coated Fe3O4MNPs as well as their thermal decomposition characteristics was examined using
Fourier transform infrared spectroscopy and Thermogravimetric Analyzer equipment, respectively. HT-1080
cells were cultured until the logarithmic phase of growth, and MTT assay was successfully carried out to
evaluate the possible cytotoxic effects of umbelliprenin-coated Fe3O4 MNPs in viable cells in vitro. The
results demonstrated that umbelliprenin has moderate antiproliferative effects with IC50 value of 50 µg/mL.
However, the combination of umbelliprenin and Fe3O4 MNPs showed the IC50 value of 9 µg/mL. In other
words, cell proliferation decreased to the remarkably-low proportion of 45% after treating cells with
umbelliprenin-coated Fe3O4 MNPs. This suggests that with the aid of nanoparticles as carriers, natural
products may have even broader range of medical applications in future.+98 21 66461178.
verdi).
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
Despite many efforts, side effects of anti cancer drugs are still
considered as a major drawback in chemotherapy of malignant
diseases [1–3]. In recent years, there has been increasing interest in
the use of new drug delivery systems to reduce the side effects of
these drugs [4–6]. Novel drug delivery systems mainly include
nanotubes [7,8], liposomes [9–11], dendrimers [12,13] and nanopar-
ticles [14–16]. The potential biomedical applications of Fe3O4
magnetite nanoparticles (MNPs) are well discussed in literature
[17,18]. Due to their magnetic properties, these nanomaterials have
received particular attention as possible drug carriers [19,20].
It was previously demonstrated that the uptake of anticancer
agents by targeted tumor cells improves when used in conjugation
with Fe3O4 MNPs as carrier [21]. Moreover, a signiﬁcant difference in
biological activities of a natural metabolite and its Fe3O4 MNPS-conjugated form was observed in both in vitro and in vivo models,
suggesting that the use of nanoparticles in conjugation with
therapeutic agents may improve the therapeutic index of these
compounds [22]. However, the toxicity of metal-based nanoparticles
is a major health and environmental issue and has raised many
fundamental criticisms in this area [23,24].
To date, thousands of secondary metabolites have been isolated
from plants and microorganisms and there is an unprecedented
attention towards potential biomedical applications of these com-
pounds. However, a large number of these natural products are
insoluble in biological ﬂuids and their bioavailability should be
improved by different chemical or physical treatments [25–27]. In
addition, some of these natural products may more efﬁciently
penetrate into target cells when combined with a carrier [25–27].
Umbelliprenin (Fig. 1) is a highly-insoluble, bio-active sesquiterpene
coumarin which was speciﬁcally selected for its numerous biological
features such as: hepatoprotection, gelatinase inhibition, cancer
chemoprevention, antigenotoxicity, and antileishmanial properties
[28–31]. Additionally, recent experiments revealed the activity of two
umbelliprenin derivatives against inﬂuenza A (H1N1) virus [32].
Fig. 1. The chemical structure of umbelliprenin.
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and the antiproliferative effect of the new combination was
determined to see whether umbelliprenin-coated Fe3O4 MNPs is an
efﬁcient combination in chemotherapy of HT-1080 cells. The
underlying hypothesis was that by conjugating umbelliprenin with
Fe3O4MNPs, the cytotoxicity of this compound, as well as its efﬁciency
may be improved.
2. Experimental procedures
2.1. Synthesis of Fe3O4 magnetic nanoparticles
Fe3O4 MNPs were prepared at room temperature by a previously
reported method [33]. Brieﬂy, deionized water (200 mL) was
deoxygenated by bubbling nitrogen gas for 1.5 h, then 50 mL of
NH4OH (1 M)was added and themixturewas stirredwithmechanical
agitation at 1000 rpm. Then, amounts of 6.76 g FeCl3·6H2O
(2.5 mmol) and 4.97 g FeCl2·4H2O (2.5 mmol) were separately
dissolved in 50 mL distilled water to make 0.5 M solutions. Subse-
quently, amounts of 10 mL ferrous chloride and 20 mL ferric chloride
solutions were added to the ammonium hydroxide solution and the
reaction mixture was stirred for 2.5 min at 1000 rpm. At this stage, a
black precipitate formed which was washed four times with
deionized water. Finally, using a magnet, the prepared Fe3O4 MNPs
were separated from the solution.
2.2. Preparation of umbelliprenin-coated Fe3O4 nanoparticles
In order to coat umbelliprenin on the surface of Fe3O4 MNPs, a
precipitationmethodwas used as follows: umbellipreninwas isolated
and identiﬁed from Ferula persica var. persica using a previously
described method [34]. A 30 mg/mL chloroform solution of umbelli-
prenin was prepared and reserved in a sealed container. Fe3O4 MNPs
(100 mg) were dispersed in 100 mL distilled water. Thereafter,
amount of 2 mL chloroform solution of umbelliprenin was added
drop-by-drop to the suspension of Fe3O4 MNPs over a 5 min period
under continuously stirring (300 rpm) condition, and using a
laboratory magnetic stirrer. The resulting mixture was maintained in
a static regime at 45 °C for 15 min. Umbelliprenin-coated Fe3O4 MNPs
was separated from the solution by a magnet. Finally, the capped
nanoparticles were washed three times with distilled water. A stock
suspension of Fe3O4 MNPs and umbelliprenin-coated Fe3O4 MNPs
were prepared (10 mg/mL) and used for antiproliferative bioassay.
2.3. Characterization of nanoparticles
Fe3O4 MNPs were characterized by transmission electron micros-
copy (model EM 208 Philips) and energy-dispersive spectroscopy
(EDS). Moreover, the surface chemistry of the umbelliprenin-coated
Fe3O4 MNPs was studied using Fourier transform infrared spectros-
copy (Nicolet Magna 550). Thermal decomposition characteristics of
umbelliprenin-coated Fe3O4 MNPs were determined using a Thermo-
gravimetric Analyzer TGA equipment as well.
2.4. Cell culture
Human ﬁbrosarcoma cell line (HT-1080) was seeded in 96-well
tissue culture plates. Cells were maintained in a RPMI-1640 medium,supplemented with 5% fetal calf serum plus antibiotics, 5% CO2 and
saturated humidity, in 37 °C. The Fibrosarcoma-HT-1080 cell line was
obtained from the National Cell Bank of Iran (NCBI), Pasteur Institute
of Iran, Tehran (Iran).
2.5. Dose–response analysis
In order to study the possible effect of umbelliprenin-Fe3O4 MNPs
on growth and proliferation of viable cells, the dose-dependent
response of HT-1080 cells were monitored after treatment with
umbelliprenin-coated Fe3O4 MNPs. For this purpose, the number of
viable HT-1080 cells was assessed based on the uptake of thiazolyl
blue tetrazolium bromide (MTT, Sigma) by cells. A MTT-based assay
was carried out based on our previous publication [35]. In brief,
20,000 cells were seeded in a 100-µL RPMI 1640 growthmedium in 96
well plates. After incubation at 37 °C for 24 h, the medium was
replaced with either control medium, or a medium containing
increasing concentrations of Fe3O4 MNPs or umbelliprenin-coated
Fe3O4 MNPs (10, 20, 40 and 80 µg/mL).Cells were further incubated at
37 °C in 5% CO2 for 24 h. Then, 50 μl of MTT solution (0.5 mg/mL) in
PBS was added to each well. The plates were wrapped in foil and
incubated for 4 h at 37 °C in 5% CO2. To solubilize formazan crystals,
the medium was replaced with 100 µL DMSO (dimethyl sulfoxide) in
eachwell, followed by 12.5 µL Sorensen's glycine buffer (0.1 M glycine
plus 0.1 M NaCl equilibrated to pH=10.5 with 0.1 M NaOH). After
15 min incubation in dark condition, O.D. values of plates were
measured in λ=570 nm by microplate reader (Dynatech Laborato-
ries, Inc, United States). Cell density was calculated according to the
previously-determined standard curve. Each experiment was repeat-
ed three times and MTT assay was performed in 3 replicates for each
experiments. The percentage of inhibition rate (IR) was measured
using the following equation:
IR %ð Þ = 1−ODexp= ODcon × 100
where ODexp and ODcon were optical densities of treated and
untreated cells, respectively. Finally, The percentage-inhibition curve
was obtained by plotting “the percentage of inhibition” (i.e.
[absorbance of test wells /absorbance of control wells] /100) against
the concentration of cytotoxic compounds, compared to control (i.e.
untreated) cells.
3. Results
3.1. Preparation and characterization of Fe3O4 MNPs
As mentioned earlier, Fe3O4 MNPs were chemically synthesized
and their shape and size properties were studied by transmission
electron microscopy. Fig. 2A demonstrates the representative TEM
image of drop-coated chemically-synthesized Fe3O4 MNPs [33].
According to Fig. 2A, the broad surface area of Fe3O4 MNPs together
with themagnetic forces between particles could cause a considerable
agglomeration among Fe3O4 MNPs [36]. Moreover, the particle size
histogram of Fe3O4 MNPs (Fig. 2B) revealed that magnetic nanopar-
ticles varied in size from 6 to 16 nm with an average size of 10 nm.
Energy dispersive spectroscopic (EDS) analysis of Fe3O4 MNPs
revealed the presence of Fe and O elements peaks which conﬁrmed
the existence of iron-oxide nanoparticles (Fig. 3). It is worth-
mentioning that the additional peaks of copper and carbon elements
occurred due to the grid used for TEM imaging.
After drop-by-drop addition of the organic solution of umbellipre-
nin to Fe3O4 MNPs slurry, umbelliprenin molecules were precipitated
on the surface of the Fe3O4 nanoparticles by the ratio of 1/4 w/w ( this
means that each milligram of coated Fe3O4 MNPs contained almost
0.25 mg umbelliprenin). This ratio was determined gravimetrically by
weighing the coated Fe3O4 MNPs before and after it was washed with
Fig. 2. TEM image of chemically-synthesized Fe3O4 MNPs (A) and umbelliprenin-coated Fe3O4 MNPs (C). The particle size distribution histograms of free Fe3O4 MNPs (B) and
umbelliprenin-coated Fe3O4 MNPs (D) revealed that both types are well below 20 nm in size, with an average size of 10 nm. The magnetic forces between Fe3O4 MNPs, fortiﬁed by
high surface area of nanoparticles caused agglomeration among MNPs.
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umbelliprenin-coated Fe3O4 MNPs and Fig. 2D represents the
histogram of size distribution among umbelliprenin-coated Fe3O4
MNPs. Comparing Fig. 2B with D, it is noticeable that the size
distributionpatternswere very similar betweenumbelliprenin-coated
and non-coated Fe3O4 MNPs. Both coated and non-coated particles
were below 20 nm in size, with the average size of 10 nm.Fig. 3. Energy dispersive spectroscopic (EDS) analysis of Fe3O4 MNPs conﬁrmed the
presence of Fe and O atoms and the existence of iron-oxide nanoparticles. Additional
peaks of copper and carbon elements occurred due to the grid used for TEM imaging.The associated IR spectroscopic data of umbelliprenin, Fe3O4
MNPs, and umbelliprenin-coated Fe3O4 MNPs is outlined in Table 1.
The results conﬁrmed the presence of umbelliprenin on the surface of
synthesized Fe3O4 MNPs. Fig. 4 demonstrates weight loss of
umbelliprenin-coated Fe3O4 MNPs as a function of temperature;
determined by thermogravimetric method. Theweight loss in the TGA
curve indicated carbon oxidation; thereby proved the presence of
organic moieties in the sample. This literally conﬁrmed that Fe3O4
MNPs were truly coated with umbelliprenin molecules.
3.2. Antiproliferative effects of Fe3O4 MNPs
Antiproliferative effects of umbelliprenin-coated Fe3O4 MNPs,
umbelliprenin alone, and Fe3O4 MNPs alone were evaluated in vitro
at different concentrations of human Fibrosarcoma cell line (HT-
1080). The cytotoxicity analysis of samples showed a direct dose–Table 1
The Fourier transform infrared spectroscopy data of Fe3O4 MNPs, umbelliprenin and
umbelliprenin-coated Fe3O4 MNPs.
Sample Main peaks wave numbers (cm−1)
Fe3O4 MNPs 584
Umbelliprenin-coated Fe3O4 MNPs 2919, 1721, 1603, 1460, 1132, 835, 569
Umbelliprenin alone 2914, 1721, 1608, 1460, 1127, 830
Fig. 4. Weight loss of umbelliprenin-coated Fe3O4 MNPs as a function of temperature,
determined by thermogravimetric method. This weight loss in the TGA curve indicated
carbon oxidation which proved the presence of organic moieties in the sample, thereby
conﬁrming that Fe3O4 MNPs were truly coated with umbelliprenin molecules.
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concentrations (Fig. 5). Samples were found to have different
cytotoxicities on HT-1080 cells, with umbelliprenin-coated nanopar-
ticles being the most potent. The antiproliferative effect of test
compounds increased in the order: Fe3O4 MNPsbumbellipreninb
umbelliprenin-coated Fe3O4 MNPs. Moreover, the concentration
necessary to cause 50% cell death (IC50) was above 80 µg/mL in cells
treated with Fe3O4 MNPs alone, and 50 µg/mL in cells treated with
umbelliprenin. However, umbelliprenin-coated Fe3O4 MNPs pro-
duced the same effect (i.e. 50% cell death) at the very low
concentration of 9 µg/mL. In other words, the new combination of
umbelliprenin and Fe3O4 MNPs was more potent than each alone. As
clear in Fig. 5, at the concentrations of 10 and 20 µg/mL, Fe3O4 MNPs
showed no remarkable antiproliferative effect in viable cells, while the
concentrations of 40 and 80 µg/mL Fe3O4 MNPs, moderately reduced
the proportion of viable cells to 80% and 63%, respectively. The
cytotoxicity curve for umbelliprenin alone followed an almost similar
pattern, though sharper. The percentage of viable cells sharply
decreased from 95% at the concentration of 10 µg/mL to 31% at
80 µg/mL.
In contrast, however, only the low concentration of 10 µg/mL
umbelliprenin-coated Fe3O4MNPs (equivalent to the concentration of
approximately 2.5 µg/mL pure umbelliprenin), drastically reduced theFig. 5. Antiproliferative effect of Fe3O4 MNPs, umbelliprenin and umbelliprenin-coated
Fe3O4 MNPs against human Fibrosarcoma cell line (HT-1080).proportion of viable cells by more than 55%. In higher concentrations,
this proportion declined steadily, until it reached the remarkably-low
amount of 29% at 80 µg/mL concentration.
4. Discussion
Numerous reports have been published in literature on cytotoxi-
city and chemo-preventive properties of umbelliprenin [37–39].
However, the efﬁciency of this compound in conjugation with Fe3O4
MNPs has not been yet investigated. Here, we report that the
antiproliferative effect of umbelliprenin enhanced in tumor cells
when coated on the surface of Fe3O4 MNPs.
As mentioned earlier, Fe3O4 MNPs, umbelliprenin and umbelli-
prenin-coated Fe3O4 MNPs, all showed antiproliferative effects on
Fibrosarcoma cell line, increasing in the order: Fe3O4 MNPsb
umbellipreninbumbelliprenin-coated Fe3O4 MNPs. It is noticeable
that based on previous and current studies, umbelliprenin has
antiproliferative effect on Fibrosarcoma cell lines Wehi 164 and HT
1080 in concentrations not below 10 µg/mL [31]. However, our results
demonstrated that when coated on Fe3O4 MNPs surface, umbellipre-
nin have antiproliferative effect, even at the low concentration of
2.5 µg/mL. This literally means that much lower amounts of
umbelliprenin will be needed to produce the same antiproliferative
effect as umbelliprenin alone. As described in Section 3.1, during
precipitation process, umbelliprenin molecules were precipitated on
the surface of Fe3O4MNPs by the ratio of 1/4 w/wwhich indicates that
each milligram of coated Fe3O4 MNPs averagely contained 0.25 mg
pure umbelliprenin compound. Therefore, it is deducible from Fig. 5,
that the concentration of 20 µg/mL umbelliprenin caused 20% cell
death. However, when combined with Fe3O4 MNPs, the average
concentration of 20 µg/mL umbelliprenin (equivalent to the concen-
tration of 80 µg/mL umbelliprenin-Fe3O4 MNPs) caused more than
70% cell death. Thus, it is concluded that by coating umbelliprenin on
the surface of Fe3O4 MNPs, either the antiproliferative effects of this
compound enhances up to 350% (3.5 fold increase), or the required
amount of umbelliprenin could be lowered to 25%.
As mentioned before, many natural products have low solubility in
biological ﬂuids, which reduces their efﬁciency in in vivo models.
Therefore, it is possible that Fe3O4 MNPs may be efﬁcient carriers for
natural compounds, by altering their water-solubility properties.
In terms of chemical bonding, two main interactions are expected
to occur between Fe3O4 MNPs and umbelliprenin: Firstly, the
hydrogen bonds may form between carbonyl oxygen and two steric
oxygen atoms of umbelliprenin (Fig. 1) and hydroxylated form of
Fe3O4 MNPs. Secondly, the Fe3O4 MNP-umbelliprenin system may be
stabilized through interactions between carbonyl oxygen atom and
the Fe chelating agent in Fe3O4 crystal. It is possible that these
interactions make umbelliprenin-coated Fe3O4 MNPs a suitable
carrier with bipolar properties which penetrates into both hydrophilic
and hydrophobic (i.e. cell membrane) ﬂuids at the same time. In
addition, the carbonyl oxygen group of umbelliprenin increases the
rigidity of the molecule, hence increasing its stability on the surface of
Fe3O4 MNPs and thus improving its performance. These assumptions
led us to assume that the new amphipathic features of Fe3O4 MNP-
umbelliprenin combination may have helped improve its antiproli-
ferative effects in Fibrosarcoma cells.
5. Conclusion
In this work, we reported the antiproliferative effect of umbelli-
prenin (IC50=50 µg/mL) and we suggested that the combination of
Fe3O4 MNPs and umbelliprenin is signiﬁcantly more cytotoxic
(IC50=9 µg/mL) than umbelliprenin alone. This means that the
antiproliferative effect of umbelliprenin enhances up to 350% when
coated on the surface of Fe3O4 MNPs. The result is of particular value
since it demonstrates that by using metallic nanoparticles in
1042 M.R. Khorramizadeh et al. / Materials Science and Engineering C 30 (2010) 1038–1042combination therapy, lower amounts of these materials may be
needed. This may reduce the potential hazards of using metallic
nanoparticles. It also suggests that compounds with natural origin
may be considered as suitable and potent antiproliferative agents
when combined with inorganic nanoparticles such as Fe3O4 MNPs.
Further investigations are needed to determine the antiprolifera-
tive effect of umbelliprenin-coated Fe3O4 MNPs in other cell lines.
Moreover, studies on cytotoxic effects of umbelliprenin-coated Fe3O4
MNPs in animal models will be of great value.
In conclusion, our ﬁnding suggests that with the aid of nanopar-
ticles, natural products may have an even broader range of medical
applications in the future.
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